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Abstract
Background: Alzheimer’s disease (AD) mutations in amyloid precursor protein (APP) and presenilins (PSENs) could
potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ1–43 is more prone to
aggregation and has higher toxic properties than the long-known Aβ1–42. However, a direct effect on Aβ1–43 in
biomaterials of individuals carrying genetic mutations in the known AD genes is yet to be determined.
Methods: N = 1431 AD patients (n = 280 early-onset (EO) and n = 1151 late-onset (LO) AD) and 809 control
individuals were genetically screened for APP and PSENs. For the first time, Aβ1–43 levels were analysed in
cerebrospinal fluid (CSF) of 38 individuals carrying pathogenic or unclear rare mutations or the common PSEN1
p.E318G variant and compared with Aβ1–42 and Aβ1–40 CSF levels.
The soluble sAPPα and sAPPβ species were also measured for the first time in mutation carriers.
Results: A known pathogenic mutation was identified in 5.7% of EOAD patients (4.6% PSEN1, 1.07% APP) and in 0.3%
of LOAD patients. Furthermore, 12 known variants with unclear pathogenicity and 11 novel were identified. Pathogenic
and unclear mutation carriers showed a significant reduction in CSF Aβ1–43 levels compared to controls (p = 0.037; <
0.001). CSF Aβ1–43 levels positively correlated with CSF Aβ1–42 in both pathogenic and unclear carriers and controls (all
p < 0.001). The p.E318G carriers showed reduced Aβ1–43 levels (p < 0.001), though genetic association with AD was not
detected. sAPPα and sAPPβ CSF levels were significantly reduced in the group of unclear (p = 0.006; 0.005) and p.E318G
carriers (p = 0.004; 0.039), suggesting their possible involvement in AD. Finally, using Aβ1–43 and Aβ1–42 levels, we could
re-classify as “likely pathogenic” 3 of the unclear mutations.
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Conclusion: This is the first time that Aβ1–43 levels were analysed in CSF of AD patients with genetic mutations in the
AD causal genes. The observed reduction of Aβ1–43 in APP and PSENs carriers highlights the pathogenic role of longer
Aβ peptides in AD pathogenesis. Alterations in Aβ1–43 could prove useful in understanding the pathogenicity of
unclear APP and PSENs variants, a critical step towards a more efficient genetic counselling.
Keywords: Alzheimer’s disease (AD), Amyloid-β 1–43 (Aβ1–43), Cerebrospinal fluid (CSF), Alzheimer mutations, Oxford
Nanopore Technologies (ONT) long-read sequencing
Background
AD is the most common cause of dementia, character-
ized by progressive cognitive decline and memory loss,
accounting for 50 to 75% of all dementia patients [1].
Based on the disease onset, AD is classified into early-
onset AD (EOAD, < 65 years) and late-onset AD (LOAD,
> 65 years) [2]. Mutations in amyloid precursor protein
(APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2)
have been identified as a cause of both EOAD and
LOAD [3, 4] explaining 10% of all EOAD and about 2%
of LOAD patients [4, 5]. The overproduction and aggre-
gation of amyloid-β (Aβ) in the brain are thought to be
the major causal events triggering AD that ultimately
lead to neuronal loss [6]. Aβ peptides aggregate in the
brain forming amyloid plaques, which together with
neurofibrillary tangles (NFTs) of hyper-phosphorylated
tau protein are the AD pathological hallmarks [6, 7]. Aβ
is generated from cleavages of APP through at least two
distinct and mutually exclusive pathways. In the so-
called non-amyloidogenic pathway, APP is cleaved by α-
secretase and γ-secretase to produce three fragments: a
secreted C-terminal fragment (sAPPα), p3 and the APP
intracellular domain (AICD) [4]. In the amyloidogenic
(pathogenic) pathway, APP is cleaved by β-secretase,
followed by γ-secretase cleavage. The cleavage by β-
secretase generates a large soluble extracellular secreted
domain (sAPPβ) and C99. The latter undergoes add-
itional cleavages by γ-secretase to generate a series of
Aβ peptides 39–43 amino acids long, following two dif-
ferent pathways: Aβ1–49 > Aβ1–46 > Aβ1–43 > Aβ1–40 and
Aβ1–48 > Aβ1–45 > Aβ1–42 > Aβ1–38 [8]. Shorter peptides
can also be produced, including Aβ1–41 from Aβ1–43 [9]
and Aβ1–34 from either Aβ1–42 or Aβ1–40 [10], which is
considered a biomarker of Aβ clearance and AD pro-
gression [11]. Pathogenic mutations in APP and PSEN1
and 2 (γ-secretase’s catalytic subunits) are known to in-
fluence APP metabolism leading to the deposition of Aβ
peptides. The most abundant Aβ peptides in the cere-
brospinal fluid (CSF) resulting from APP processing are
Aβ1–38, Aβ1–40 and Aβ1–42. The latter is considered the
most pathological peptide in AD as it is most prone to
aggregation into amyloid plaques [12]. Aβ1–42 levels have
been found to be reduced in CSF of patients with AD
[13] as a result of Aβ1–42 increased production and
subsequent accumulation into plaques [14]. Further-
more, CSF Aβ1–42 levels are usually reduced up to de-
cades before the clinical symptoms of dementia appear
[15]. Thus, CSF Aβ1–42 levels are considered a core bio-
marker for early AD [16], together with total tau protein
(T-tau) (non-AD specific) and tau phosphorylated at
threonine 181 (P-tau181) (AD specific) [17]. In addition
to Aβ peptides, α and β cleaved soluble APP (sAPPα and
sAPPβ) are products of the APP metabolism which also
have been investigated as possible AD biomarkers,
though with contradicting results [18, 19]. Aβ1–42 levels
have been used for the pathological classification of AD
mutations, both in vivo and in vitro [20]. However, some
of the established AD pathogenic mutations do not show
altered Aβ1–42 levels [21]. For example, in the brain of
the PSEN1 p.R278I knock-in mice, a decrease of Aβ1–40
was accompanied by an increase of another Aβ, i.e. spe-
cies, Aβ1–43, which showed higher aggregative properties
than Aβ1–42 [21]. Interestingly, Aβ1–43 was also detected
in the brain of sporadic and familial AD patients [22–
24] supporting the hypothesis that the generation of
relatively long Aβ peptides (>Aβ1–42) could explain part
of the pathogenic effect of the known deleterious PSENs
and APP mutations [25, 26]. Furthermore, several vari-
ants identified in the causal AD genes remain of uncer-
tain significance (VUS) (www.alzforum.org/mutations;
AD/FTD Mutation Database [27]), due to lack of func-
tional studies and co-segregation with disease in rela-
tives. Understanding the role of these variants is
important for a correct clinical diagnosis, for genetic
counselling and for the selection of well-stratified patient
groups for clinical trials. The investigation of longer Aβ
peptides, including Aβ1–43, in CSF of individuals carry-
ing AD mutations or VUS could disclose possible alter-
ations of the Aβ peptide production and explain their
possible role in the AD pathogenesis. Recent studies
showed that CSF Aβ1–43 levels are significantly reduced
in individuals with AD and mild cognitive impairment
(MCI) [16, 28], as well as in EOAD patients compared
to LOAD [29], independently from the mutation status.
Studies assessing Aβ1–43 levels in CSF of PSENs and
APP mutation carriers are therefore lacking. In the
present work, we measured for the first time the Aβ1–43
levels in CSF of carriers of APP and PSENs pathogenic
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and VUS mutations and control individuals and we
compared these results to Aβ1–42 and Aβ1–40. We also
measured, for the first time in mutation carriers, sAPPα
and sAPPβ in relation to Aβ1–43, as they are less investi-
gated, but still part of the APP processing.
Methods
Study population
The study population consisted of 1431 AD patients
(62.03% [n = 889] women, average age at onset (AAO)
73.51 ± 9.81 years, range 29–96 years), ascertained in
Belgium through the neurology centres of the clinical
partners of the Belgian neurology (BELNEU) consor-
tium. All patients received a diagnosis of possible, prob-
able or definite AD according to the criteria described
by the National Institute of Neurological and Communi-
cation Disorders and Stroke Alzheimer’s Disease and Re-
lated Disorders Association (NINCDS-ADRDA) criteria
and the National Institute on Aging–Alzheimer’s Associ-
ation (NIA-AA) [30]. A positive family history of demen-
tia (i.e. at least one first-degree relative affected) was
documented in 22.22% (n = 318) of the patients. Based
on the onset age (< 65 years), 19.57% (n = 280) of the pa-
tients were classified as having early-onset AD (EOAD,
54.64% [n = 153] women, average AAO 58.22 ± 6.14, age
range 29–65 years). A Belgian control cohort of 809 in-
dividuals (73.54% [n = 595] women, average age at inclu-
sion (AAI) 70.12 ± 10.71, 31–96 years) was included in
the study. The control individuals were primarily
community-dwelling volunteers or spouses of patients.
Subjective memory complaints, neurologic or psychiatric
antecedents, and a familial history of neurodegeneration
were ruled out by means of an interview. Cognitive
screening was performed using the Mini-Mental State
Examination (cut-off score > 26) [31] and/or the Mon-
treal Cognitive Assessment test (cut-off score > 25) [32].
The spouses of patients were examined at the Memory
Clinic of ZNA Middelheim and Hoge Beuken in Ant-
werp, Belgium. CSF of additional 64 controls individuals
(AAI 68.05 ± 5.97), used in this study for comparison
purposes, were available at the Reference Centre for
Biological Markers of Dementia (BIODEM), Department
of Biomedical Sciences, University of Antwerp. These
were primarily community-dwelling volunteers enrolled
in the BACEi program (ClinicalTrials.gov identifiers:
54861911ALZ1005 (NCT01978548); 54861911ALZ2002
(NCT02260674)) by Janssen Pharmaceutica NV, Beerse,
Belgium [33]. Subjective memory complaints, neurologic
or psychiatric antecedents, were ruled out by means of
an interview. Cognitive screening was performed using
the mini-mental state examination (cut-off score > 26).
The Clinical Dementia Rating Scale (CDR) score was 0,
and AD CSF biomarkers were within the normal range.
Genetic screening in these 64 individuals was not
performed due to the unavailability of DNA. All research
participants or their legal guardian provided written in-
formed consent for participation in genetic and clinical
studies. Clinical study protocols and informed consent
forms for patient ascertainment were approved by the
local medical ethics committees of the collaborating
medical centres in Belgium. Genetic study protocols and
informed consent forms were approved by the ethics
committees of the University Hospital of Antwerp and
the University of Antwerp, Belgium.
Mutation screening
Genomic DNA of patients and control individuals was
analysed for mutations in APP, PSEN1 and PSEN2 using
a targeted re-sequencing gene-panel as we previously de-
scribed [34]. We selected non-synonymous variants with
a minor allele frequency (MAF) < 1%, including exon-
intron boundaries for possible variants affecting splicing.
The allelic frequencies of these variants, observed in the
patient group, were assessed in the control cohort and
Genome Aggregation database (gnomAD, lastly accessed
in January 2020) [35]. In addition, PSEN1 rs17125721
A > G, p.E318G variant (MAF 1.927%, gnomAD), consid-
ered a possible risk modifier (https://www.alzforum.org/
mutations/psen1-e318g) and Apolipoprotein E (APOE)
genotypes were analysed. Variants with a read depth
below 20X, with Genoqual value below 99 and with an
imbalanced wild-type/variant read depth (cut-off > 3)
were considered false positives. All the selected variants
were validated by Sanger sequencing (BigDye Termin-
ator Cycle sequencing kit v3.1) on the ABI 3730 DNA
Analyser (both Applied Biosystems). Sequences were
analysed using SeqManII or novoSNP software packages
[36]. To screen for APP locus duplications, multiplex
amplicon quantification (MAQ) was used on 280 EOAD
patients, as previously described [37]. Briefly, multiplex
PCR amplification of 5 target and 11 reference ampli-
cons was performed using fluorescently labelled primers.
The amplification products were size separated on ABI
3730 automatic sequencer using GeneScan-500 LIZ (Ap-
plied Biosystems) as internal size standard. Data analysis
was performed using the MAQ software (MAQs) pack-
age (www.vibgeneticservicefacility.be). One sample carry-
ing the APP duplication and four different control
samples were used as positive and negative controls,
respectively.
CSF biomarker analysis
CSF were available for a subset of 38 mutation carriers:
18 carriers of pathogenic and VUS mutations (MAF <
1%) (AAO 71.58 ± 11.24 years, range 56–85 years) and
20 carriers of PSEN1 p.E318G variant (AAO 78.09 ±
6.62 years, range 62–87 years) as well as 64 control indi-
viduals (AAI 68.05 ± 5.97, cfr. “Study population”).
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Lumbar puncture, CSF sampling and handling have been
performed according to standard protocols [12]. Samples
were stored at − 80 °C until analysis. CSF concentrations
of Aβ1–42 and Aβ1–40 were measured using enzyme-
linked immunosorbent assay (ELISA) with commercially
available single parameter ELISA kits at the BIODEM la-
boratory as previously described [38]. Aβ1–43 levels were
measured using the amyloid beta (1–43) (FL) Aβ kit
(IBL) and both sAPPα and sAPPβ using sAPPα/sAPPβ
kit (Meso Scale Discovery). Concerning T-tau and P-
tau181 levels, these were previously measured using
hTAU Ag and PHOSPHO-TAU(181P) (INNOTEST),
respectively, and the BIODEM laboratory performed the
ELISA for the 38 mutation carriers and the Sahlgrenska
University Hospital (Sweden) for the 64 control individ-
uals. For this reason, we did not perform statistical ana-
lysis on either T-tau or P-tau181 amongst the groups,
but we only reported the values of the measurements,
which are part of the phenotypic characterization of the
cohort. All calibration standards and CSF samples were
analysed in duplicate. Only mean values with a coeffi-
cient of variation (CV) of the replicates less than or
equal to 20% were included in the analysis.
Statistical analyses
Statistical analyses were performed in SPSS version 24,
and graphs were made using GraphPad Prism8. A logis-
tic regression analysis was performed in the AD and
control cohorts, to determine whether patients had
higher probability than controls to carry both the com-
mon PSEN1 p.E318G and APOE ε4 genotype. With a
similar model, we further tested the prevalence of APOE
ε4 between EOAD and LOAD cohorts and of APOE
ε4ε4 between EOAD and LOAD cohorts.
For the CSF biomarker analysis, the mutation carriers
were divided in three different groups: carriers of known
pathogenic mutations, of VUS and of PSEN1 p.E318G.
First, a Kolmogorov-Smirnov test was performed to
check for normal distribution. Since most variables did
not follow a normal distribution, non-parametric tests
were used. Differences amongst groups were tested using
Kruskal-Wallis. Post hoc analysis with pairwise compari-
sons was carried out (adjusted p value < 0.05). To iden-
tify whether an association between two markers was
present, the Spearman’s rho correlation tests were per-
formed. Correlation coefficients were extracted from
each group (controls, known pathogenic, VUS, PSEN1
p.E318G) separately. After correction for multiple testing
(Bonferroni’s correction), p values < 0.005 or below were
considered to be statistically significant. Receiver operat-
ing characteristic (ROC) curves were additionally per-
formed to assess the diagnostic accuracy of the
individual biomarkers, and the area under each ROC
curve (AUC) was calculated. Finally, explanatory cut-offs
were identified as the concentration of specific bio-
marker that maximizes sensitivity and specificity of the
test (Youden’s index).
Transcript analysis
To inhibit non-sense-mediated mRNA decay (NMD), 1 ×
106 lymphoblast cells of the double mutation carrier (pa-
tient 16; PSEN1 p.G183V, PSEN1 p.P49L), of the single
carrier (sibling of patient 16; PSEN1 p.G183V) and of 4
non-carriers as negative controls were incubated with 150
mg/mL cycloheximide (CHX) (Sigma-Aldrich) at 37 °C for
4 h. To generate cDNA, total RNA was extracted using
the RiboPureTM kit (Life Technologies) followed by a
DNase treatment (TURBODNase Kit, Invitrogen). First-
strand complementary DNA was synthesized using the
SuperScript III First-Strand Synthesis System (Life Tech-
nologies) using random hexamer primers. Full-length
PSEN1 transcript sequencing was subsequently performed
on a MinION sequencing platform (Oxford Nanopore
Technologies (ONT)) based on a modernized cDNA se-
quencing protocol [39]. Briefly, cDNA amplification of
PSEN1 full transcript was carried out with Platinum® Taq
DNA Polymerase (Clontech Laboratories) using exonic
primers, designed with Primer3Plus [40], with a 5′ ONT
adapter. In a second PCR round, using PCR Barcoding Kit
96 (EXP-PBC096; ONT), sample-specific barcodes were
added. Samples were pooled equimolar and processed ac-
cording to ONT SQK-LSK109 library preparation.
Sequencing was performed on a Mk1 MinION (MIN-
101B), using FLO-MIN106 flow cells. Base calling and
barcode de-multiplexing were performed with Albacore
(v2.2.5). Sequencing reads were subsequently aligned
using minimap2 [41], with splice-aware parameters. Only
full-length PSEN1 spanning sequencing reads were
retained for further analysis. Relative quantifications of
splice junctions were calculated by dividing the number of
junction-supporting reads by the total number of reads
spanning the PSEN1 transcript in R (R Core Team, 2017).
Results
Mutation screening
The genetic screening identified a total of 41 mutations
in 54 individuals (41/1431, 2.86% AD, 13/809, 1.60%
controls). The identified variants are listed in Table S1
(Additional file). Fourteen were known pathogenic mu-
tations (4 in APP, 10 in PSEN1) (www.alzforum.org/mu-
tations, lastly accessed in January 2020) and were
identified in 19 patients (19/1431, 1.33%) and 1 control
individual (1/809, 0.12%). Specifically, 1.07% (3/280) of
EOAD patients carried known pathogenic mutations in
APP and 4.6% (13/280) in PSEN1. Furthermore, in
0.086% (1/1151) and 0.26% (3/1151) of LOAD patients,
known pathogenic mutations were identified in APP and
PSEN1, respectively.
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In addition, 12 previously reported variants with un-
clear pathogenicity (5 in APP, 2 PSEN1, 5 PSEN2)
were detected in 12 patients (12/1431, 0.84%) and 7
controls (7/809, 0.86%). Three were known benign
variants (2 APP, 1 PSEN2) found in 7 patients (7/
1431, 0.49%) and 2 controls (2/809, 0.24%). Lastly, 11
rare variants were novel (5 in APP, 1 in PSEN1, 5 in
PSEN2) absent from gnomAD and mutation data-
bases, observed in 8 patients (8/1431, 0.56%) and 3
control individuals (4/809, 0.49%). There was no sig-
nificant difference between the prevalence of APOE
ε4 in EOAD (57%) and LOAD (55%) (p = 0.48). The
prevalence of APOE ε4 was higher in EOAD (60%)
than LOAD (55%) only on individuals without any
APP or PSENs mutations, but this difference was still
not significant (p = 0.15). We found a significant dif-
ference in the prevalence of APOE ε4ε4 between
EOAD (20%) and LOAD (9%) when considering all
individuals (p < 0.001). This difference in the preva-
lence of APOE ε4ε4 (EOAD 20%; LOAD 9%) was
similar when running the same model only on indi-
viduals without any APP or PSENs mutations (p <
0.001).
APOE genotypes of the mutation carriers are listed in
Table S1 (Additional file). Amongst the patients, two
were double mutation carriers: patient 16, carrying both
PSEN1 p.G183V and PSEN1 p.P49L, with LOAD path-
ology (Figure S1, Additional file), and patient 11, carry-
ing both APP p.G625_S628del and PSEN1 p.P355S. The
risk variant PSEN1 p.E318G was detected in 45 patients
(45/1431, 3.14%) and 24 controls (24/809, 2.96%). No
significant association was found between PSEN1
p.E318G and AD, regardless of APOE ε4 genotype (p =
0.29 and p = 0.51, respectively). Furthermore, in the
screened cohort, APP locus duplications were not
detected.
CSF biomarker analysis
The CSF biomarkers were analysed comparing three
groups of mutation carriers: (1) known pathogenic, (2)
VUS and (3) PSEN1 p.E318G to control individuals. A
significant reduction of CSF Aβ1–43 levels was detected
in all three carrier groups (all p < 0.05; Table 1; Fig. 1).
For each carrier of a known pathogenic mutation or a
VUS, Aβ1–43 levels are shown in the bar plot (Fig. 2).
Similarly, Aβ1–42 CSF levels were significantly reduced in
all three carrier groups (all p < 0.05; Table 1; Fig. 3).
Comparison of CSF Aβ1–40 levels did not show a signifi-
cant difference amongst all groups (p = 0.66).
The Aβ1–43/Aβ1–40 and Aβ1–42/Aβ1–40 ratios were sig-
nificantly reduced in all three carrier groups (all p < 0.05,
Table 1; Figs. 1, 2 and 3). Aβ1–43/Aβ1–42 ratio was sig-
nificantly reduced in the VUS and PSEN1 p.E318G car-
rier groups (both p < 0.001) (Fig. 1). Aβ1–43 significantly
correlated with Aβ1–42 in all four groups (r > 0.87, all
p < 0.001). Aβ1–43 and Aβ1–42 were significantly corre-
lated with Aβ1–40 in the controls and PSEN1 p.E318G
group (all r > 0.63, all p < 0.001), while there was a cor-
relation between Aβ1–42 with Aβ1–40 in the VUS group,
but not significant after Bonferroni’s correction (r = 0.65,
p = 0.015). Both CSF Aβ1–43 and Aβ1–42 were able to dif-
ferentiate the corresponding controls from the group of
known pathogenic and PSEN1 p.E318G (AUCs > 0.9;
Table S2, Additional file), while in the VUS group the
differentiation was slightly less efficient (AUCs 0.84–
0.89; Table S2, Additional file).
CSF sAPPα and sAPPβ levels were significantly re-
duced in both VUS (both p < 0.05) and PSEN1 p.E318G
carriers (both p < 0.04) (Table 1; Fig. 4).
Aβ1–43 and Aβ1–42 showed a positive correlation with
both sAPPα and sAPPβ only in the control group (all
r > 0.48, all p < 0.001). Aβ1–40 correlated with sAPPα
only in the control group (r = 0.6, p < 0.001) and with
Table 1 Significance levels (adjusted p values) of the markers compared amongst groups
Pathogenic vs controls VUS vs controls p.E318G vs controls
Est. St. p value Est. St. p value Est. St. p value
Aβ1–43 39.93 2.90 0.037 37.36 4.15 < 0.001 45.43 5.99 < 0.001
Aβ1–43/Aβ1–40 42.92 3.12 0.018 40.08 4.45 < 0.001 46.97 6.20 < 0.001
Aβ1–43/Aβ1–42 28.45 2.07 0.384 37.37 4.15 < 0.001 44.85 5.91 < 0.001
Aβ1–42 40.32 2.93 0.033 32.33 3.59 0.003 41.42 5.46 < 0.001
Aβ1–42/Aβ1–40 43.52 3.14 0.015 33.59 3.73 0.002 43.87 5.79 < 0.001
sAPPα 12.54 0.91 1.0 31.04 3.45 0.006 26.90 3.55 0.004
sAPPβ 14.06 1.02 1.0 31.32 3.48 0.005 21.87 2.89 0.039
Aβ1–43/sAPPα 37.44 2.73 0.064 21.18 2.35 0.186 38.79 5.12 < 0.001
Aβ1–43/sAPPβ 36.31 2.64 0.082 21.49 2.39 0.169 41.25 5.44 < 0.001
Kruskal-Wallis was performed to assess differences amongst groups. Significance level p < 0.05 (adjusted p values). Abbreviations: Est. test estimate, St. standard
test statistic
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sAPPβ in the control (r = 0.65, p < 0.001) and VUS groups
(r = 0.75, p = 0.003). Aβ1–43/sAPPα and Aβ1–43/sAPPβ
CSF levels were significantly lower in PSEN1 p.E318G car-
riers compared to controls (p < 0.001) (Fig. 4). Aβ1–43/
sAPPα and Aβ1–43/sAPPβ CSF levels also showed a trend
to be decreased in carriers of the pathogenic mutations,
although this difference was not statistically significant
(p = 0.06 and p = 0.08, respectively) (Table 1; Fig. 4). The
AUCs for both sAPPα and sAPPβ were low (AUCs =
0.625; Table S2, Additional file). CSF levels for each
marker (Aβ1–43, Aβ1–42, Aβ1–40, sAPPα, sAPPβ) are
summarised in Table 2. ROC curve analysis for all bio-
markers are listed in Table S2 (Additional file), and the
AUC curves are shown in Figures S2-S3 (Additional file).
PSEN1 full transcript analysis
The effect of the PSEN1 p.G183V and PSEN1 p.P49L
double mutation on PSEN1 alternative transcript gener-
ation in patient-derived RNA was examined with ONT
MinION sequencing, because of a previously reported
effect of this mutation on exon skipping in both
Fig. 1 CSF levels of Aβ1–43, Aβ1–43/Aβ1–40 and Aβ1–43/Aβ1–42 ratios in the three mutation carrier groups compared to controls. Scatter plots show
Aβ1–43 (a), Aβ1–43/Aβ1–40 (b) and Aβ1–43/Aβ1–42 (c) CSF levels in controls and in carriers of known pathogenic mutations, of VUS and of PSEN1
p.E318G. Values of mean ± SD are given. p value indicators correspond to the values assessed with Kruskal-Wallis: *p < 0.05, ***p < 0.0001
Fig. 2 Aβ1–43 CSF levels in carriers of known pathogenic mutations or VUS compared with the control group. The CSF levels of Aβ1–43 for each
carrier of a known pathogenic mutation (in stripes) or a VUS (in gray) are shown in the bar plots together with the control group (in black). Error
bars indicate the SD of the duplicate measurements for the mutation carriers and the average of the values for the controls. The asterisks (*)
indicate the carriers of one APOE ε4 allele
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HEK293 cells [42] and mice brain [43]. Both the double
mutation carrier (patient 16; PSEN1 p.G183V, PSEN1
p.P49L) and the single PSEN1 p.G183V carrier show the
skipping of exon 6 in 20% of the sequencing reads from
the cDNA obtained from the lymphoblast cells treated
with CHX and 5% from the untreated (Fig. 5). Exons 6–
7 skipping was also detected, but it was a rarer event
(Figure S4, Additional file). The analysis of the transcript
surrounding the PSEN1 p.P49L variants did not show
splicing alterations (data not shown).
Discussion
Mutation screening
The APP, PSEN1 and PSEN2 mutation screening in
1431 AD patients and 809 control individuals identified
known pathogenic mutations in 5.7% of EOAD (16/280)
and 0.3% of LOAD (4/1151) patients and in 0.12% (1/
809) of the controls, in line with what it is usually ob-
served [4, 5]. The carrier of the APP p.A713T mutation
considered with unclear pathogenicity but actually show-
ing segregation with the disease in another study [44]
was asymptomatic at the age of inclusion in our cohort
(age > 65 years) [34]. This APP mutation is known to
have a wide onset age range; therefore, it is not surpris-
ing to identify asymptomatic carriers [34, 44]. Amongst
the known pathogenic mutations, two were also found
in AD patients with more than 65 years of onset: the
known pathogenic PSEN1 p.C263F, identified in five pa-
tients with onset age range of 53–70, and the PSEN1
p.G183V, previously identified in a patient with fronto-
temporal dementia and Pick-type tauopathy [42] (further
discussed later in the text). These findings highlight the
importance to screen the causal AD genes also in LOAD
patients [5]. The genetic screening identified also two
double mutation carriers: patient 11 carrying the APP
p.G625_S628del and the PSEN1 p.P355S, both VUS, and
patient 16 having the PSEN1 p.G183V and the novel
p.P49L.
PSEN1 p.G183V and p.P49L mutation carrier
Patient 16 received a diagnosis of probable AD (age at
onset > 65). Clinically, patient 16 showed amnestic pres-
entation without other remarkable signs or symptoms.
Single-photon emission computed tomography (SPECT)
displayed a moderate hypoperfusion of the bilateral par-
ietal, temporal and frontal lobe, compatible with AD.
Magnetic resonance imaging (MRI) showed age-related
atrophy and multiple supratentorial lacunary infarcts.
Neuropathological examination showed a mild atrophy
of the frontotemporal gyri (Figure S1, Additional file),
but no FTD symptoms were reported in patient 16. The
patient was pathologically diagnosed with definite AD
(Montine stage A3B3C3), with an accent on the neuro-
fibrillary pathology (Figure S1). The sibling of patient 16
also carried the PSEN1 p.G183V, but not the PSEN1
p.P49L, and was diagnosed with probable AD. Both
PSEN1 mutations therefore segregated independently in
the family [45]. The PSEN1 p.G183V was previously
identified in a patient diagnosed with frontotemporal de-
mentia (FTD) and Pick-type tauopathy [42]. The brain
lesions in patient 16 were however different from those
of the published FTD patient, where severe frontotem-
poral atrophy and Pick-like pathology were described
[42]. There were no intranuclear neuronal inclusions in
patient 16 and no signs of Pick’s disease. Thus, the Pick’s
Fig. 3 CSF levels of Aβ1–42 and Aβ1–42/Aβ1–40 ratio in the three mutation carrier groups compared to controls. Scatter plots show Aβ1–42 (a) and
Aβ1–42/Aβ1–40 (b) CSF levels in controls and in carriers of known pathogenic mutations, of VUS and of PSEN1 p.E318G. Values of mean ± SD are
given. p value indicators correspond to the values assessed with Kruskal-Wallis: *p < 0.05, **p < 0.01, ***p < 0.0001
Perrone et al. Alzheimer's Research & Therapy          (2020) 12:108 Page 7 of 14
pathology detected in the FTD patient [42] is probably
independent of this PSEN1 p.G183V mutation. The
PSEN1 p.G183V is located in the last nucleotide of the
exonic splice donor site of exon 6, and experiments in
HEK293 cells and mice showed the formation of alterna-
tive transcripts with skipping of exons 6 and exon 6–7,
which are likely degraded by the non-sense-mediated
mRNA decay control mechanism (NMD) [42, 43]. Our
PSEN1 transcript analysis with ONT minION sequen-
cing, in patient-derived biomaterials, confirmed that
PSEN1 p.G183V led to the formation of transcripts lack-
ing exons 6 and 6–7, which are indeed degraded by
NMD. Only a small amount of these alternative tran-
scripts remains in the cells (≤ 5%) and they unlikely
interfere with the wild-type PSEN1. The presence of the
second PSEN1 mutation (p.P49L) could drive the disease
in patient 16.
Reduced Aβ1–43 CSF levels in APP and PSENs mutation
carriers
CSF of 38 APP, PSEN1 and PSEN2 mutation carriers,
both known pathogenic and VUS, was available and used
to investigate for the first time the CSF Aβ1–43 levels. A
significant reduction of CSF Aβ1–43 levels was observed
in carriers of pathogenic mutations (13/18), of VUS (9/
13) and of carriers of PSEN1 p.E318G (18/20) compared
to controls. This reduction was comparable with CSF
Aβ1–42 levels. CSF Aβ1–43 levels positively correlated
with Aβ1–42 in all mutation carrier groups but correlated
with Aβ1–40 only in PSEN1 p.E318G mutation carriers
and controls. Aβ1–43/Aβ1–40 ratio was significantly re-
duced in all three mutation carrier groups, while Aβ1–43/
Aβ1–42 ratio only in the VUS and PSEN1 p.E318G
groups, as previously shown for AD patients (independ-
ently from the mutation status) [9].
Fig. 4 CSF levels of sAPPα, sAPPβ, Aβ1–43/sAPPα and Aβ1–43/sAPPβ ratios in the three mutation carrier groups compared to controls. Scatter plots
show sAPPα (a), sAPPβ (b), Aβ1–43/sAPPα (c) and Aβ1–43/sAPPβ (d) CSF levels in controls and in carriers of known pathogenic mutations, of VUS and of
PSEN1 p.E318G. Values of mean ± SD are given. p value indicators correspond to the values assessed with Kruskal-Wallis: *p < 0.05, ***p < 0.0001
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Table 2 Summary of CSF marker levels for each mutation carrier
Individual identifier Mutation APOE Aβ1–43 Aβ1–42 Aβ1–40 sAPPα sAPPβ T-tau P-tau181
P Patient 12 PSEN1 p.A79V 34 10 490 3836 99 90 NA NA
Patient 13 PSEN1 p.A79V 33 18 531 4833 87 101 959 136
Patient 17 PSEN1 p.C263F 33 20 679 8165 252 268 458 73
Patient 21 PSEN1 p.C263F 33 36 1202 9117 130 141 281 55
Patient 24 PSEN1 p.R269H 33 8 393 4063 127 114 640 77
V Patient 10 APP p.P91L 34 11 516 4026 42 44 287 44
Control 3 APP p.S198P 33 29 1190 7838 111 125 248 47
Patient 5 APP p.R328W 33 50 1598 8134 72 86 371 76
Control 4 APP p.R328W 34 13 483 8679 161 184 NA NA
Patient 6 APP p.R499H 34 9 513 4486 74 78 440 51
Patient 7 APP p.E599K 34 14 816 8065 179 200 > 1200 225
Patient 8 APP p.E599K 33 25 630 5184 116 110 633 104
Patient 29 PSEN1 p.D40del 33 14 618 6641 122 103 615 82
Patient 31 PSEN2 p.R62C 34 15 613 6823 57 73 NA NA
Patient 32 PSEN2 p.R62H 33 44 1699 9048 122 127 407 59
Patient 34 PSEN2 p.R62H 34 17 561 4269 110 103 783 82
Patient 36 PSEN2 p.S130L 33 14 578 4631 73 81 340 54
Patient 40 PSEN2 p.T153S 33 7 373 2340 39 34 212 32
List of carriers of APP and PSENs known pathogenic (P) and VUS (V) mutations with CSF available. Notes: all carriers had AD diagnosis except control 3 and control
4, who were controls at the moment of inclusion. Control 4 developed vascular dementia at follow-up (AAO 75 years). Patients in bold are EOAD patients (AAO
range 56–65 years). Values for Aβ1–43, T-tau and P-tau181 are in pg/mL. Underlined values and values in bold, for Aβ1–43, Aβ1–42, Aβ1–40, sAPPα and sAPPβ, are
respectively higher and lower levels of the markers based on the exploratory cut-offs (Table S2, Additional file). Normal cut-offs: T-tau
< 297 pg/mL; P-tau181 < 57 pg/mL
Fig. 5 Transcript analysis of PSEN1 in patient 16. The bar graph shows the relative quantifications of exon 6 in the double carrier (patient 16, PSEN1
p.G183V, p.P49L), single carrier (PSEN1 p.G183V) and non-carrier lymphoblast cells CHX treated (CHX) and untreated (UNT). Relative quantifications of
splice junctions were calculated by dividing the number of junction-supporting reads by the total number of reads spanning the PSEN1 transcript. The
quantifications for both CHX and UNT of the non-carriers are reported as averages (values of SD for CHX ± 0.001052869 and for UNT ± 0.000671837)
(a). Visualization of the PSEN1 exon 6 cDNA MinION reads from Integrative Genomic Viewer software (IGV). Sequencing reads of PSEN1 cDNA of the
double and single carriers confirm exon 6 skipping due to the PSEN1 p.G183V mutation (b)
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While longer Aβ peptides (e.g. Aβ1–42 and Aβ1–43) pro-
mote aggregation and neurotoxicity, Aβ1–40 appears to act
protectively [46]. Moreover, CSF Aβ1–40 levels did not dif-
fer significantly between AD patients and controls in a
meta-analysis [19]. Therefore, we speculated that the posi-
tive correlation of Aβ1–43 with Aβ1–42, but not with Aβ1–
40 (except in PSEN1 p.E318G carriers), further supports
the involvement of Aβ1–43 in AD. It is however still un-
clear why Aβ1–40 would be unaltered and lacking of cor-
relation with Aβ1–43 in the mutation carrier groups, as it
is related to the process of Aβ1–43. It is plausible that a
possible decrease of Aβ1–40 in CSF would only be visible
or measurable during the earlier stages of the disease
when mostly all neurons are still intact, rather than in
later stages (when it is normally measured), when Aβ pro-
duction is higher but less neurons are preserved. Alterna-
tively, it is possible that the cleavage of the C99 fragment
by γ-secretase may be heavily impaired at the third cleav-
age step when Aβ1–40 is generated from Aβ1–43, as sug-
gested by Kakuda et al. [47] for the pathogenic PSEN1
p.R278I, which would result in negligible levels of Aβ1–40
and unusually high levels of Aβ1–43. Furthermore, a recent
study found a correlation between Aβ peptide length and
plaque load (Aβ1–43 > Aβ1–42 > Aβ1–40), indicating that
longer Aβ peptides have an increased tendency towards
accumulation in the brain [23], thus explaining their lower
CSF levels. Further analysis of the shorter Aβ species Aβ1–
41, Aβ1–37 (from Aβ1–43) Aβ1–38 (from Aβ1–42) and Aβ1–34
(from either Aβ1–43 or Aβ1–42) are however needed to bet-
ter clarify the role of longer Aβ peptides in AD and the
pathogenic events linked to Aβ process, degradation and
clearance in the presence of APP and PSENs mutations
[9–11].
The production of longer Aβ peptides (> Aβ1–42), in-
cluding Aβ1–43, in the pathogenesis of AD is receiving
increased attention [23, 25, 26, 29, 48]. Studies showed
that the PSEN1 p.L435F produces primarily Aβ1–43,
which was detected in the brain plaques [49] and in-
duced pluripotent stem cell (iPSC) neurons [50] of pa-
tients carrying this mutation. Another work suggested
that the APP mutations affect the endopeptidase activity
of γ-secretase, leading to Aβ1–42 formation, while PSEN1
mutations inhibit its carboxypeptidase activity, releasing
multiple longer peptides including Aβ1–42 and Aβ1–43
[25]. Unfortunately, the number of mutations we investi-
gated was not sufficient to make similar observations.
Based on the CSF biomarker analyses performed, some
of the PSENs VUS mutations analysed showed biomarker
levels comparable to the known pathogenic mutations: for
instance, the PSEN1 p.40del, which was described for the
first time in an EOAD patient with prominent frontal fea-
tures and no family history of dementia [51]. This variant
was considered “most likely benign” or causing a small in-
crease in risk based on its frequency in gnomAD [52].
However, an in vitro assay, testing the mutant PSEN1 abil-
ity to cleave the APP-C99 fragment, revealed a robust de-
crease in Aβ1–42 production and undetectable levels of
Aβ1–40 [8]. Our data is in favour of an involvement of
PSEN1 p.40del in Aβ alteration, showing decreased CSF
levels of both Aβ1–43 and Aβ1–42 and unaltered Aβ1–40
levels in the patient carrier, and also in line with a recent
study showing increased Aβ1–42 and unaltered Aβ1–40 in
the medium collected from mice neuro-2A cells trans-
fected with the plasmid containing the PSEN1 p.40del mu-
tation [53]. The PSEN2 p.S130L variant was first reported
in an Italian family, but segregation with disease could not
be determined [54]. Another study described a carrier of
this variant who had an autopsy-confirmed AD diagnosis
[55]. The pathogenicity of PSEN2 p.S130L is currently un-
clear, since it did not affect Aβ1–42 levels or Aβ1–42/Aβ1–40
ratio in in vitro experiments [56]. According to an algo-
rithm proposed by Guerreiro et al. [57], this variant has
been considered “probably pathogenic.” In line with this
classification, we found a significant reduction of both
Aβ1–43/Aβ1–40 and Aβ1–42/Aβ1–40 ratios in the patient car-
rier, pointing out to a possible pathogenicity of PSEN2
p.S130L. Finally, the carrier of the novel PSEN2 p.T153S
variant also had reduced CSF levels of Aβ1–43 and Aβ1–42,
comparable to the known pathogenic mutations. In light
of these data, we could consider those mutations as “likely
pathogenic”, since they seem to affect or interfere with Aβ
production. Furthermore, it is important to note that the
three mutation carriers were all APOE ε4 negative, mean-
ing that the detected Aβ alteration is likely due to the mu-
tations themselves without an effect of APOE. For the
APP variants, instead, we could not drive conclusions on
the variants pathogenicity. In fact, all the APP variants
analysed were located outside the pathogenic exons
16–17, encoding for the Aβ domain. Furthermore, two
carriers of APP variants were considered controls at the
moment of inclusion: control 3 carried the APP
p.S198P variant and CSF analysis did not reveal Aβ al-
terations; control 4, carrying the APP p.R328W and
having altered CSF marker levels, developed vascular
dementia at follow-up. Of note, control 3 but not con-
trol 4 was APOE ε4 negative. We would like to stress
the importance to further investigate a possible inter-
ference of the APP variants outside the Aβ domain in
AD. There was variability of Aβ1–43 CSF levels between
the carriers of the same mutations (PSEN1 p.A79V,
PSEN1 C263F, APP R328W, APP E599K, PSEN2 R62H,
Fig. 2; Table 2). We initially hypothesized an effect of
APOE ε4 on the decreased Aβ1–43 CSF levels as already
demonstrated for Aβ [58]. This seemed a valid hypoth-
esis for all mutations but one (PSEN1 p.C263F, Fig. 2;
Table 2). However, a recent study showed a reduced in-
fluence of APOE on Aβ1–43 aggregation in cerebrovas-
cular cells [48].
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Aβ1–43 CSF levels in PSEN1 p.E318G carriers
To better understand the role of PSEN1 p.E318G on AD
pathology, we investigated the CSF Aβ1–43 levels in car-
riers, detecting a reduction. This PSEN1 variant is sug-
gested to be an AD risk modifier as it was associated
with high levels of P-tau181P and T-tau [59, 60]. More-
over, carriers of both APOE ε4 and PSEN1 p.E318G vari-
ant were reported to have a higher risk of developing
LOAD than APOE ε4 carriers without the PSEN1 variant
[59, 60]. In our study, however, the PSEN1 p.E318G vari-
ant did not show an association with AD regardless of
APOE ε4 genotype, which is in line with the study of
Hippen et al. [61]. A recent analysis of CSF Aβ1–42, T-
tau and P-tau181 in asymptomatic p.E318G carriers of a
large LOAD Italian family did not reveal any changes in
CSF markers [62]. The levels of Aβ1–43 were not mea-
sured and therefore not allowing a direct comparison.
Soluble species sAPPα and sAPPβ
We also detected reduced levels of sAPPα and sAPPβ in
the three carrier groups analysed compared to controls,
but statistical significance was not detected in the group
of the known pathogenic mutations. Our results are dif-
ferent from other studies where no difference in sAPPα
and sAPPβ levels was observed between patients and
controls [19]. Of note, in these studies, the mutation sta-
tus of the patients was not described [19].
We report that both sAPPα and sAPPβ positively cor-
related with Aβ1–43 and Aβ1–42 only in the control group
but not in the mutation carriers. This result is in line
with another study where the correlation between Aβ1–
42 and sAPPα or sAPPβ in AD patients was not signifi-
cant [63]. We cannot explain why both sAPPα and
sAPPβ levels would be reduced in the mutation carriers
and correlate with the control group. In fact, sAPPα and
sAPPβ should not be affected by the presence of AD
mutations, which affect γ-secretase activity, while sAPPα
and sAPPβ are respectively generated by α- and β-
secretases in the earlier steps, before Aβ production.
However, the data of CSF sAPPα and sAPPβ levels in
AD are unclear [19] and there are no studies so far that
have measured CSF sAPPα and sAPPβ in AD mutation
carriers. The possible involvement of sAPP fragments in
AD is still not fully understood [18], and the interpret-
ation of the results remains therefore challenging. It is
suggested that sAPPα enhances neurogenesis and has a
neuro-protective role, and it is involved in neurotrans-
mission and synaptic plasticity [64]. A recent study,
however, showed that all fragments of sAPP acted as ag-
onists of a specific GABA receptor (GABAB-R1a) and
would therefore explain their role in neurotransmission
and plasticity [65]. In fact, a fragment derived from
sAPPα inhibited synaptic transmission in mouse hippo-
campus. Additional studies in carriers of AD mutations
are essential to fully understand the involvement of
sAPP in AD.
Limitations
A potential limitation of this study is the small cohort
size used to analyse Aβ1–43 and the other markers in
CSF of APP and PSENs mutation carriers, despite the
genetic screening was performed in a relatively large AD
population. As we know, APP and PSENs mutation car-
riers are extremely rare [4], as well as the availability of
their biomaterials. Therefore, a replication study was not
performed. The availability of a larger control cohort
allowed us to reach satistical significance when analysing
Aβ1–43 CSF levels. Unfortunately, age at onset, gender
and APOE genotype could not be used as covariates in
the analysis, because the number of mutation carriers
was not sufficient for the statistical test. Our pilot study
is nevertheless relevant because it highlights the involve-
ment of Aβ1–43 in AD and adds missing information re-
garding specific mutations to very recent studies
published during these last 2 years [23, 25, 48]. As CSF
Aβ1–43 has never been studied before in CSF of APP and
PSENs mutation carriers, the results need to be inter-
preted with caution and more studies are needed to rep-
licate these findings in larger cohorts. Analysis of the
shorter Aβ peptides (e.g. Aβ1–34, Aβ1–37, Aβ1–38, Aβ1–41)
could provide a more comprehensive interpretation of
our results. Lastly, in our study, it was not possible to as-
sess the difference between PSEN1 and APP mutations
in affecting γ-secretase and Aβ generation [25]; there-
fore, this aspect warrants further follow-up, also in terms
of interpretation of novel and VUS mutations in the AD
genes.
Conclusions
In this study, CSF levels of the long Aβ peptide Aβ1–43
were investigated for the first time in carriers of known
pathogenic and unclear (VUS) APP and PSENs muta-
tions. We observed a significant reduction of CSF Aβ1–
43 levels and a positive correlation with Aβ1–42 in all mu-
tation carrier groups. We suggested the re-classification
of three VUS into “likely pathogenic”, as their biomarker
levels were comparable to the known pathogenic muta-
tions. We added important information on the debatable
genetic modifier PSEN1 p.E318G and we were able to
clarify the role of PSEN1 p.G183V, using ONT long-read
sequencing, considered so far pathogenic, but probably
not involved in AD.
From a clinical perspective, our data could prove use-
ful. A recent study showed that Aβ43 was cleared more
than Aβ42 in plaques of patients treated with Aβ im-
munotherapy [23]. These are important data that open
new possibilities for personalized medicine in patients
with AD, who have a high Aβ1–43 load in the brain. For
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these reasons, Aβ1–43 could be considered an added AD
biomarker together with the others already in use. Des-
pite the small study cohort, the data presented here cor-
roborate previous findings on Aβ1–43 [21, 25, 26, 29, 49],
suggesting a possible involvement of longer Aβ peptides
in the AD pathophysiology.
CSF levels of sAPPα and sAPPβ were also analysed for
the first time in AD mutation carriers, where their levels
were reduced compared to controls. Based on the recent
analysis on sAPP fragments as regulators of (GABA)
neurotransmission, further investigation in AD is im-
portant to study more in detail this pathway to open
new venues for therapy strategies.
Finally, functional work using patient biomaterials can
prove valuable to better understand the pathogenicity of
unclear AD mutations. This will be useful for patient
stratification for clinical trials, genetic counselling and
therapy development.
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(Patient 16; PSEN1 p.G183V, PSEN1 p.P49L), the single carrier (sibling of Pa-
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treated (CHX) and untreated (UNT). Relative quantifications of splice junc-
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